Molecular imaging of prostate cancer with PET

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1685-1688

  Jadvar, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Correlative imaging; Imaging; Molecular; Molecular imaging; Oncology; PET; PET CT; PET MRI; Prostate; Radiopharmaceuticals

Indexed keywords

ANDROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

AMINO ACID TRANSPORT; ANTIGEN EXPRESSION; BONE MATRIX; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; GLUCOSE METABOLISM; HUMAN; LIPOGENESIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TRANSPORT KINETICS; ANIMAL; CORRELATIVE IMAGING; IMAGING; MALE; METABOLISM; METHODOLOGY; MOLECULAR; NEOPLASM; ONCOLOGY; PET; PET/CT; PET/MRI; PROSTATE; PROSTATE TUMOR; SCINTISCANNING; PROCEDURES;

CANCER; CORRELATIVE IMAGING; IMAGING; MOLECULAR; MOLECULAR IMAGING; ONCOLOGY; PET; PET/CT; PET/MRI; PROSTATE; RADIOPHARMACEUTICALS;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891706485     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126094     Document Type: Review

References (28)

1. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 2013;40:244-258.
2. Moore AL, Dimitropoulou P, Lane A, et al. Population-based prostate-specific antigen in the UK leads to a stage migration of prostate cancer. BJU Int. 2009;104:1592-1598.
3. Presti J Jr. Does the yield of prostate cancer biopsy and repeat biopsy justify the frequency of their use? Nat Clin Pract Urol. 2008;5:246-247.
4. Bruce JY, Lang JM, McNeel DG, et al. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012;10:716-722.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
6. 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637-643.
7. 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013;54:1195-1201.
8. Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat. 2012;98:1-10.
9. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-2041.
10. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013;54:699-706.
11. 11C-acetate positron emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. June 13, 2013 [Epub ahead of print].
12. 11Ccholine positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013;189: 1308-1313.
13. 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106-117.
14. Evangelista L, Zattoni F, Guittilla A, et al. Choline PET and PET/CT and biochemical relapse of prostate cancer. Clin Nucl Med. 2013;38:305-314.
15. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1):S36-S40.
16. 18F] fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nucl Med Biol. 2013;40:670-675.
17. 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852-861.
18. 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1): 11-17.
19. Fox J, Blanc E, Schoder H, et al. Diversity of biology in castrate resistant prostate cancer [abstract]. J Nucl Med. 2009;50(suppl 2):136P.
20. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13:951-962.
21. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:396-407.
22. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR. 2012; 199:278-291.
23. Jadvar H, Colletti PM. Competitive advantage of PET/MRI. Eur J Radiol. June 18, 2013 [Epub ahead of print].
24. 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol. 2013;48:256-262.
25. 64Cu-labeled magnetic resonance nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem. 2010;21:715-722.
26. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
27. 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.
28. Park H, Wood D, Hussain H, et al. Introducing parametric fusion PET/MR imaging of primary cancer. J Nucl Med. 2012;53:546-551.